Veru Inc. is a biopharmaceutical company focused on developing and commercializing novel small‑molecule therapies for cardiometabolic and inflammatory diseases. The company’s lead program centers on enobosarm, an oral selective androgen receptor modulator being evaluated to mitigate loss of muscle mass and function in patients undergoing weight loss treatment with GLP‑1–based therapies, aiming to support higher-quality weight reduction by preserving lean tissue. Veru Inc. is also advancing sabizabulin, an oral microtubule disruptor with broad anti-inflammatory properties under development for chronic inflammation associated with atherosclerotic cardiovascular disease and related conditions. In addition, the company maintains programs in oncology and acute respiratory distress syndrome, with late-stage development assets targeting breast and prostate cancer and viral-related ARDS. Veru Inc. currently generates revenue primarily from the United States, South Africa, and other international markets through its commercial sexual health products, including ENTADFI for benign prostatic hyperplasia and the FC2 Female Condom (Internal Condom). Headquartered in Miami, Florida, Veru Inc. operates as a single business segment within the healthcare and biotechnology industry.
Website2916 North Miami Avenue
Miami, FL, 33127
United States
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety-- --Oral sabizabulin had a good safety profile and promising efficacy in previous first-in-man Phase 1b/2 clinical study of 80 subjects with castration resistant and taxane resistant met
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming 2026 Cantor Global Healthcare Conference, in New York City, New York, on September 9, 2026 from 2:10 pm – 2:40 pm Easte
Motley Fool Press Release.
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients – -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent
Investors talking about VERU also mention
What share of all stock conversation is about VERU?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% 0 |
Of the messages about VERU that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | 81.82% 0 | 58.62% -24.67 | ||
| Bearish | — | — | 18.18% 0 | 41.38% +24.67 |
Of the messages about VERU that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | 12.5% | 60.57% | ||
| Technical Analysis | — | — | 87.5% | 33.42% | ||
| Earnings | — | — | 0% | 1.31% | ||
| Analysts | — | — | 0% | 2.87% | ||
| Controversies | — | — | 0% | 1.31% | ||
| Macro | — | — | 0% | 0.52% |
Of the messages about VERU, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 52.17% | 41.67% | ||
| Newcomers | — | — | 47.83% | 58.33% |